uniQure N.V. has grown revenue −45% a year over three years and −14% a year over five. Revenue growth, 3-year annual rate: −45% (Biotechnology median +17%). Revenue growth, 5-year rate: −14%, growth has slowed since the five-year average. Years of annual history on file: 12, FY2014 to FY2025, as filed.

QUREuniQure N.V.

Healthcare

$22.57+63% 1Y

$22.57

$9.0352 weeks$70.59

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+282.0 points), but revenue shrinking (−10% year on year).

1 good, 1 to watch, 1 without data

Revenue trend−10% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −14% a year.

Margin direction+282.0 points operating

Trailing-twelve-month operating margin, -1103.5% now against -1385.6% a year earlier.

All from SEC EDGAR, as of Mar 31, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is QURE growing?

uniQure N.V. has grown revenue −45% a year over three years and −14% a year over five.

−45%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −14%
Revenue growth, 5-year rate · −45% over three · growth has slowed since the five-year average
Years of annual history on file: 12
Years of annual history on file · FY2014 to FY2025, as filed

Details›